Regulation of plasma aldosterone levels by metoclopramide: A reappraisal of its mechanism from dopaminergic antagonism to serotonergic agonism

Neuropharmacology

Volumn 36, Issue 6, 1997, Pages 763-768

  Rizzi, C A ^a   Mierau, J ^b   Ladinsky, H ^a  

^a Boehringer Ingelheim Italia SpA   (Italy)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

5 HT4 receptors; Aldosterone; Humans; Metoclopramide

Indexed keywords

DOPAMINE RECEPTOR BLOCKING AGENT; METOCLOPRAMIDE; SEROTONIN AGONIST;

ALDOSTERONE BLOOD LEVEL; BLOOD BRAIN BARRIER; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW; VOMITING;

ALDOSTERONE; ANIMALS; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; METOCLOPRAMIDE; PROTEIN BINDING; SEROTONIN; SEROTONIN AGONISTS;

EID: 0030788098     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00025-7     Document Type: Review

References (65)

1. Aguilera G. and Catt K. J. (1984) Dopaminergic modulation of aldosterone secretion in the rat. Endocrinology 114: 176-181.
2. Amenta F., Chiandussi L., Mancini M., Ricci A., Schena M. and Veglio F. (1994). European Journal of Endocrinology 131: 91-96.
3. Andrews P. L. R., Rapeport W. G. and Sanger G. J. (1988) Neuropharmacology of emesis induced by anti-cancer therapy. Trends in Pharmacological Science 9: 334-341.
4. 4 receptor desensitization in colliculi neurons. Molecular Pharmacology 42: 808-816.
5. Berkowitz D. M. and McCallum R. W. (1980) Interaction of levodopa and metoclopramide on gastric emptying. Clinical and Pharmacological Therapeutics 27: 414-420.
6. Braley L. M., Menachery A. I. and Williams G. H. (1983) Specificity of metoclopramide in assessing the role of dopamine in regulating aldosterone secretion. Endo-crinology 112: 1352-1357.
7. Brogden R. N., Carmine A. A., Heel R. C., Speight T. M. and Avery G. S. (1982) Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspesia and as an antiemetic. Drugs 24: 360-400.
8. Brown R. D., Wisgerhof M., Jiang N.-S., Kao P. and Hegstad R. (1981) Effect of metoclopramide on the secretion and metabolism of aldosterone in man. Journal of Clinical Endocrinology and Metabolism 52: 1014-1018.
9. Cannon J. G. (1975) Chemistry of dopaminergic agonists. Advances in Neurology 9: 177-183.
10. Carey R. M., Thorner M. O. and Ortt E. M. (1980) Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Journal of Clinical Investigation 66: 10-18.
11. Contesse V., Hamel C., Delarue C., Lefebvre H. and Vaudry H. (1994) Effect of a series of 5-HT4 receptor agonists and antagonists steroid secretion by the adrenal gland in vitro. European Journal of Pharmacology 265: 27-33.
12. Contesse V., Hamel C., Lefebvre H., Dumuis A., Vaudry H. and Delarue C. (1996) Activation of 5-hydroxytryptamine4 receptors causes calcium influx in adrenocortical cells: involvement of calcium in 5-hydroxytryptamine-induced steroid secretion. Molecular Pharmacology 49: 481-493.
13. Defer G., Guezennec C. Y., Fraitag B. and Lhoste F. (1987) Effects of ketanserin on cardiovascular, sympatho-adrenal and endocrine systems during physical exercise in man. Fundamental Clinical Pharmacology 1: 135-143.
14. Degli Uberti E. C., Trasforini G., Margutti A. R., Rotola C. A. and Pansini R. (1982) Effect of ketanserin, a new inhibitor of 5-HT2 receptors, on plasma renin activity and aldosterone levels in normal subjects. Hormone Research 16: 244-248.
15. Degli Uberti E. C., Trasforini G., Margutti A. R., Rotola C. A., Bianconi M. and Pansini R. (1983) Effect of ketanserin, an inhibitor of 5-HT2 receptors, in the aldosterone-stimulating action of metoclopramide. Hormone Research 17: 160-167.
16. Delarue C., Lefebvre H., Contesse V., Héry F., Raynaud G., Kuhn J. M. and Vaudry H. (1992) Serotonin stimulates corticosteroid secretion from human adrenal gland through activation of 5-HT4 receptors coupled to adenylate cyclase. 2nd International Symposium on Serotonin. Abstract Book, p. 53. Houston, Texas, September 15-18.
17. Demura R., Naruse M., Isawa M., Onoda N., Naruse K., Yamakado M. and Demura H. (1992) A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion. Endocrinology Japan 39: 169-176.
18. Donnelly R., Elliott H. L., Meredith P. A. and Reid J. L. (1987) Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. British Journal of Clinical Pharmacology 24: 599-606.
19. Drake C. R. Jr. and Carey R. M. (1984) Dopamine modulates sodium-dependent aldosterone responses to angiotensin n in humans. Hypertension 6 (Suppl. 1): 119-123.
20. Dumuis A., Sebben M. and Bockaert J. (1989) The gastro-intestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn-Schmiedeberg's Archives of Pharmacology 340): 403-410.
21. Elliot H. L., Donnelly R. and Reid J. L. (1988) Effects of ketanserin on peripheral vascular pressor mechanisms in essential hypertension. Journal of Cardiovascular Pharmacology 11 (S1): S62-S66.
22. Fozard J. R. and Mobarok Ali A. T. M. (1978) Blockade of neuronal tryptamine receptors by metoclopramide. European Journal of Pharmacology 49): 109-112.
23. Fraser R. (1987) Dopamine regulation of aldosterone secretion: an open question? Journal of Endocrinology 112: 179-181.
24. Ganguly A. (1984) Dopaminergic regulation of aldosterone secretion: how credible? Clinical Science 66: 631-637.
25. Girbes A. R. J., Smit A. J., Meijer S. and Reitsma W. D. (1990) Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Nephron 56: 179-185.
26. Girbes A. R. J., Veldhuisen D. J. van, Smit A. J., Drent-Bremer A., Meijer S. and Reitsma W. D. (1991) Renal and neurohumoral effects of ibopamine and metoclopramide in normal man. British Journal of Clinical Pharmacology 31: 701-704.
27. Grandy D. K., Zhang Y., Bouvier C., Zhou Q.-Y., Johnson R. A., Allen L., Buck K., Bunzow J. R., Salon J. and Civelli O. (1991) Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Proceedings of the National Academy of Science U.S.A. 88: 9175-9179.
28. Hampton T. and Ganguly A. (1986) Metoclopramide fails to stimulate aldosterone secretion and inhibits serotonin-mediated aldosterone secretion in the rat. Hormone Metabolism Research 18: 754-756.
29. Harrington R. A., Hamilton C. W., Brogden R. N., Linkewich J. A., Romankiewicz J. A. and Heel R. C. (1983) Metoclopramide: an updated review of its pharmacological properties and clinical use. Drugs 25: 451-494.
30. Henwood J. M. and Todd P. A. (1988) Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 36: 11-31.
31. Horn P. T. and Murphy M. B. (1990) New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy. Drugs 40: 487-492.
32. Idres S., Delarue C., Lefebvre H. and Vaudry H. (1991) Benzamide derivatives provide evidence for the involvement of a 5-HT4 receptor type in the mechanism of action of serotonin in frog adrenocortical cells. Molecular Brain Research 10: 251-258.
33. Lang C. C., Rahman A. R. and Struthers A. D. (1991) Atrial natriuretic factor inhibits metoclopramide stimulated aldosterone release in man. British Journal of Clinical Pharmacology 32: 51-56.
34. Lefebvre H., Contesse V., Delarue C., Feuilloley M., Hery F., Grise P., Raynaud G., Verhofstad A. A. J., Wolf L.-M. and Vaudry H. (1992) Serotonin-induced stimulation of cortisol secretion from human adrenocortical tissue is mediated through activation of a serotonin4 receptor subtype. Neuroscience 47: 999-1007.
35. Lefebvre H., Contesse V., Delarue C., Soubrane C., Legrand A., Kuhn J.-M., Wolf L.-M. and Vaudry H. (1993) Effect of the 5-HT4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex. In vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 77: 1662-1666.
36. Lefebvre H., Contesse V., Delarue C., Legrand A., Kuhn J. M., Vaudry H. and Wolf L. M. (1995) The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man. Journal of Clinical Endocrinology and Metabolism 80: 504-507.
37. Lefebvre H., Contesse V., Delarue C., Kuhn J. M., Vaudry H. and Wolf L. M. (1996) Lack of effect of the serotonin4 receptor agonist zacopride on ACTH secretion in normal man. European Journal of Clinical Pharmacology 51: 49-51.
38. Li Kam Wa T. C., Freestone S., Samson R. R., Johnston N. R. and Lee M. R. (1993) A comparison of the effects of two putative 5-hydroxytryptamine renal prodrugs in normal man. British Journal of Clinical Pharmacology 36: 19-23.
39. Linnik M. D., Butler B. T., Gaddis R. R. and Ahmed N. K. (1991) Analysis of serotonergic mechanisms underlying benzamide-induced gastroprokinesis. Journal of Pharmacology and Experimaental Therapeutics 259: 501-507.
40. Mantero F., Opocher G., Boscaro M. and Armanini D. (1982) Effect of serotonin on plasma aldosterone in man. Journal of Endocrinological Investigation 5: 97-99.
41. Mantero F., Rocco S., Opocher G., Armanini D., Boscaro M. and D'Agostino D. (1985) Effect of ketanserin in primary aldosteronism. Journal of Cardiovascular Pharmacology 7 (Suppl. 7): S172-S175.
42. Martin G. R. and Humphrey P. P. A. (1994) Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 33): 261-273.
43. McCallum R. W., Sowers J. R., Hershman J. M. and Sturdevant R. A. L. (1975) Metoclopramide stimulates prolactin secretion in man. Clinical Research 23: 479A.
44. MacDonald T. M. (1991) Metoclopramide, domperidone and dopamine in man: actions and interactions. European Journal of Clinical Pharmacology 40: 225-230.
45. McKenna T. J., Island D. P., Nicholson W. E. and Liddle G. W. (1979) Dopamine inhibits angiotensin-stimulated aldosterone biosynthesis in bovine adrenal cells. Journal of Clinical Investigation 64: 287-291.
46. Mierau J., Schneider F. J., Ensinger H. A., Chio C. L., Lajiness M. E. and Huff R. M. (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3, and D4 receptors. European Journal of Pharmacology; Molecular Pharmacology Section 290: 29-36.
47. Monsma F. J., Shen Y., Ward R. P., Hamblin M. W. and Sibley D. R. (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molecular Pharmacology 43: 320-327.
48. Norbiato G., Bevilacqua M., Raggi U., Micossi P. and Moroni C. (1977) Metoclopramide increases plasma aldosterone in man. Journal of Clinical Endocrinology and Metabolism 45: 1313-1316.
49. North R. H., McCallum R. W., Contino C. and Havelick J. (1980) Tonic dopaminergic suppression of plasma aldosterone. Journal of Clinical Endocrinology and Metabolism 51: 64-69.
50. Schiavi G. B., Brunet S., Rizzi C. A. and Ladinsky H. (1994) Identification of serotonin 5-HT4 recognition sites in the procine caudate nucleus by radioligand binding. Neuropharmacology 33: 543-549.
51. Sechi L. A., Tedde R., Cassisa L., Pala A., Orecchioni C., Uneddu F. and Melis A. (1989) Sublingual and intravenous ketanserin versus sublingual nifedipine in the treatment of severe hypertension: a randomized study. Clinical Therapy 11: 834-840.
52. Serri O. (1987) Plasma aldosterone response to metoclopramide is unmodified by hyperprolactinemia. Hormone Research 27: 36-41.
53. Shenker Y., Gross M. D. and Grekin R. J. (1985) Peripheral serotonin 2 receptor blockade does not inhibit 5-hydroxytryptophan-induced aldosterone stimulation. Journal of Clinical Endocrinology and Metabolism 61: 1201-1204.
54. Sokoloff P., Giros B., Martres M.-P., Bouthenet M. L. and Schwartz J.-C. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151.
55. Sokoloff P., Andrieux M., Besancon R., Pilon C., Martres M.-P., Giros B. and Schwartz J.-C. (1992) Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. European Journal of Pharmacology 225: 331-337.
56. Sommers D. K., Meyer E. C. and van Wyk M. (1991) Effects of enhancement and antagonism of 5-hydroxytryptamine activity on metoclopramide-induced aldosterone secretion in man. Research in Experimental Medicine 191: 423-427.
57. Sommers D. K., Snyman J. R. and van Wyk M. (1993) Effect of metoclopramide, ondansetron and granisetron on aldosterone secretion in man. European Journal of Clinical Pharmacology 44: 337-339.
58. Stern N., Eggena P., Chandler W. and Tuck M. (1989) Effects of central and peripheral dopamine antagonism on aldosterone secretion: evidence for adrenal mechanism. American Journal of Physiology 257: E588-E594.
59. Stokes G. S., Mennie B. A. and Marwood J. F. (1986) Ketanserin and prazosin: a comparison of antihypertensive and biochemical effects. Clinical Pharmacological Therapy 40: 56-63.
60. Sunahara R. K., Guan H.-C., O'Dowd B. F., Seeman P., Laurier L. G., Ng G., George S. R., Torchia J., Van Tol H. H. M. and Niznik H. B. (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350: 614-619.
61. Tonini M., Rizzi C. A., Manzo L. and Onori L. (1991) Novel enteric 5-HT4 receptors and gastrointestinal prokinetic action. Pharmacology Research 24: 5-14.
62. Warner M. D., Gillespie H., Pavlou S.-N., Nader S. and Peabody C. A. (1992) The effect of haloperidol on aldosterone secretion. Psychoneuroendocrinology 17: 517-521.
63. Watson S. and Girdlestone D. (1996) 1996 Receptor and ion channel nomenclature supplement. Trends in Pharmacological Science, p. 28.
64. Weiner, R. I. and Bethea, C. L. (1981) Hypotalamic control of prolactin secretion. In: Prolactin (Jaffe R. B., Ed.), pp. 19-55. Elsevier North Holland Inc., New York.
65. Zhou Q.-Y., Grandy D. K., Thambi L., Kushner J. A., Van Tol H. H. M., Cone R., Pribnow D., Salon J., Bunzow J. R. and Civelli O. (1990) Cloning and expression of human and rat Dl dopamine receptors. Nature 347: 76-80.